Glutarsaeurediethylmonoamid | 30436-23-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Glutarsaeurediethylmonoamid
• 英文别名: N,N-Diethylglutaramsaeure；4-(diethylcarbamoyl)butanoic Acid；5-(diethylamino)-5-oxopentanoic acid
• CAS: 30436-23-8
• 化学式: C₉H₁₇NO₃
• mdl: MFCD03376264
• 分子量: 187.239
• InChiKey: XYMWLIJFLBQNMI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  13
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.777
• 拓扑面积：
  57.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-Diethylaminopentylethylamin 、 Glutarsaeurediethylmonoamid 生成 Bis-5-diethylaminopentylethylamin
  参考文献：
  名称：

  Edwards,D. et al., Journal of Pharmacy and Pharmacology, 1960, vol. 12, p. 137T-152T

  摘要：

  DOI：
• 作为产物：
  描述：

  戊二酸酐 、 二乙胺 以 四氢呋喃 为溶剂， 生成 Glutarsaeurediethylmonoamid
  参考文献：
  名称：

  Synthesis and SAR studies of analogues of 4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-N-thiazol-2-yl-benzamide (Lu AA41063) as adenosine A2A receptor ligands with improved aqueous solubility

  摘要：

  An adenosine A(2A) receptor antagonist may be useful for the treatment of Parkinson's disease. Synthesis and structure-activity studies starting from 4-(3,3-dimethylbutyrylamino)-3,5-difluoro-N-thiazol-2-yl-benzamide (Lu AA41063, 4) led to a novel series of human (h) A(2A) receptor antagonists with improved aqueous solubility. Compound 22 was identified as a key representative from the series, displaying sub-micromolar hA(2A) receptor affinity and excellent aqueous solubility. Compound 22 also displayed good in vitro pharmacokinetic properties and is considered a good starting point for further lead optimisation toward hA(2A) receptor antagonists with improved druggability properties. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.01.062

文献信息

• 4-Tolyl-ethynyl-octahydro-indole-1-ester derivatives
  申请人：Nozulak Joachim

  公开号：US20130303538A1

  公开（公告）日：2013-11-14

  The invention relates to compounds of the formula (I) in which the substituents are as defined in the specification; in free form or in salt form; to their preparation, to their use as medicament and to medicaments comprising them.

  该发明涉及化合物(I)的公式，其中取代基如规范中所定义；以自由形式或盐形式存在；其制备方法，其用作药物以及包含它们的药物。
• 4-tolyl-ethynyl-octahydro-indole-1-ester derivatives
  申请人：Nozulak Joachim

  公开号：US09067881B2

  公开（公告）日：2015-06-30

  The invention relates to compounds of the formula (I) in which the substituents are as defined in the specification; in free form or in salt form; to their preparation, to their use as medicament and to medicaments comprising them.

  该发明涉及公式（I）中取代基的化合物，其中取代基如规范中定义的；以自由形式或盐形式存在；它们的制备，它们作为药物的用途以及包含它们的药物。
• US9067881B2
  申请人：——

  公开号：US9067881B2

  公开（公告）日：2015-06-30
• [EN] PHOTOSENSITIVE RESIN COMPOSITION, CURED FILM, LAMINATE, METHOD FOR PRODUCING CURED FILM, AND SEMICONDUCTOR DEVICE<br/>[FR] COMPOSITION DE RÉSINE PHOTOSENSIBLE, FILM DURCI, STRATIFIÉ, PROCÉDÉ DE PRODUCTION DE FILM DURCI, ET DISPOSITIF À SEMI-CONDUCTEUR<br/>[JA] 感光性樹脂組成物、硬化膜、積層体、硬化膜の製造方法、および半導体デバイス
  申请人：FUJIFILM CORP

  公开号：WO2020054226A1

  公开（公告）日：2020-03-19

  熱塩基発生剤は式（Ｎ１）で表される。感光性樹脂組成物は、熱塩基発生剤と複素環含有ポリマーの前駆体とを含む。 式（Ｎ１）中、ＲN1およびＲN2はそれぞれ独立に１価の有機基を表し、ＲC1は水素原子または保護基を表し、Ｌは２価の連結基を表す。硬化膜は、感光性樹脂組成物を硬化してなる。積層体は、硬化膜を２層以上有し、硬化膜の間に金属層を有する。硬化膜の製造方法は、感光性樹脂組成物を基板に適用して膜を形成する膜形成工程を含む。半導体デバイスは、硬化膜または積層体を有する。
• Synthesis and SAR studies of analogues of 4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-N-thiazol-2-yl-benzamide (Lu AA41063) as adenosine A2A receptor ligands with improved aqueous solubility
  作者：Gitte Kobberøe Mikkelsen、Morten Langgård、Tenna Juul Schrøder、Mads Kreilgaard、Erling B. Jørgensen、Guillaume Brandt、Yann Griffon、Ray Boffey、Benny Bang-Andersen

  DOI：10.1016/j.bmcl.2015.01.062

  日期：2015.3

  An adenosine A(2A) receptor antagonist may be useful for the treatment of Parkinson's disease. Synthesis and structure-activity studies starting from 4-(3,3-dimethylbutyrylamino)-3,5-difluoro-N-thiazol-2-yl-benzamide (Lu AA41063, 4) led to a novel series of human (h) A(2A) receptor antagonists with improved aqueous solubility. Compound 22 was identified as a key representative from the series, displaying sub-micromolar hA(2A) receptor affinity and excellent aqueous solubility. Compound 22 also displayed good in vitro pharmacokinetic properties and is considered a good starting point for further lead optimisation toward hA(2A) receptor antagonists with improved druggability properties. (C) 2015 Elsevier Ltd. All rights reserved.